Aktienanalyse zu Liminatus Pharma Inc (LIMN)LIMNLiminatus Pharma Inc

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells. It operates in the Healthcare sector.

Liminatus Pharma Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.50, which is 92.20% lower than its year-to-date performance. The RSI is at 29.815, indicating that the stock is oversold, but this is not sufficient to justify a buy given the overall financial health. The company has a forward P/E ratio of 0, suggesting no earnings growth expectations, and a gross margin of 0%, indicating no profitability. The main risk is the company's high debt-to-equity ratio of 479.85%, which poses a significant financial risk.